Custom-Made DNA vaccine takes on advanced liver cancer

NCT ID NCT04251117

Ongoing Disease control Sponsor: Geneos Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a personalized DNA vaccine (GNOS-PV02) combined with an immune booster and the immunotherapy drug pembrolizumab in 36 adults with advanced hepatocellular carcinoma (HCC). The vaccine is custom-made for each patient based on their tumor's unique genetic markers. The goal is to see if this combination can control the cancer and improve immune response. Participants will receive the vaccine and drugs, and researchers will monitor side effects and tumor shrinkage.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HCC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HCC

Contacts and locations

Show contact details

Locations

Auckland Clinical Studies

Auckland, New Zealand
Icahn School of Medicine at Mount Sinai

New York, New York, 10029, United States
Johns Hopkins Hospital

Baltimore, Maryland, 21287, United States